H.R. 4284House115th Congress (2017-2019)Passed House

INFO Act

Introduced November 7, 2017

AI-Generated Summary

Updated April 15, 2026 at 7:08 PM UTC

The INFO Act creates a public, online dashboard that gathers and shares data on opioid and other substance‑use disorders from federal, state, tribal, nonprofit, law‑enforcement and health‑care sources. It also sets up an Interagency Substance Use Disorder Coordinating Committee to oversee and coordinate the Department of Health and Human Services’ efforts on prevention, treatment, and recovery. The bill aims to improve transparency, guide health‑care providers toward safer pain‑management options, and align federal programs with state and local initiatives.

Key Provisions

  • Within six months, HHS must launch a publicly accessible dashboard that compiles data on substance‑use disorder programs, treatment outcomes, regional trends, and best‑practice guidelines for health‑care providers.
  • The dashboard must be updated regularly and include information from federal agencies, state/local/tribal governments, nonprofits, law‑enforcement, medical experts, and research institutions.
  • Within three months, HHS must create an Interagency Substance Use Disorder Coordinating Committee, chaired by the HHS Secretary and including senior officials from multiple federal departments plus at least 17 non‑federal members representing patients, clinicians, researchers, judges, law‑enforcement, and service providers.
  • The Committee meets at least twice a year to monitor research and services, recommend improvements to federal grants and programs, evaluate regional strategies, and ensure public input is considered.
  • The Committee must publish an annual report on the dashboard summarizing its activities and findings, and after two reports the Secretary must advise Congress on whether the Committee should continue beyond its six‑year sunset.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

14 earlier actions
SenateIntro Referral Latest Action

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

June 13, 2018

View full timeline
HouseIntro Referral

Introduced in House

November 7, 2017

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

November 7, 2017

HouseCommittee

Referred to the Subcommittee on Health.

November 10, 2017

HouseCommittee

Subcommittee Consideration and Mark-up Session Held.

April 25, 2018

HouseCommittee

Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

April 25, 2018

HouseCommittee

Committee Consideration and Mark-up Session Held.

May 9, 2018

HouseCommittee

Ordered to be Reported (Amended) by Voice Vote.

May 9, 2018

HouseFloor

Mr. Walden moved to suspend the rules and pass the bill, as amended.

June 12, 2018 • 2:44 PM

HouseFloor

Considered under suspension of the rules. (consideration: CR H5034-5036)

June 12, 2018 • 2:44 PM

HouseFloor

DEBATE - The House proceeded with forty minutes of debate on H.R. 4284.

June 12, 2018 • 2:44 PM

HouseFloor

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

June 12, 2018 • 2:50 PM

HouseFloor

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

June 12, 2018 • 2:50 PM

HouseFloor

Motion to reconsider laid on the table Agreed to without objection. (text: CR H5034-5035)

June 12, 2018 • 2:50 PM

HouseFloor

The title of the measure was amended. Agreed to without objection.

June 12, 2018 • 2:51 PM

SenateIntro Referral

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

June 13, 2018

Floor Debate

3 members

What members said about H.R. 4284 on the floor

2 Republicans1 Democrat
Greg Walden
Rep. Greg WaldenR-OR-2 · Jun 12, 2018

Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 4284) to establish a Federal Coordinator within the Department of Health and Human Services, and for other purposes, as amended. Mr.…

Frank Pallone, Jr.
Rep. Frank Pallone, Jr.D-NJ-6 · Jun 12, 2018

Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise in support of H.R. 4284, the Indexing Narcotics, Fentanyl, and Opioids Act, or INFO Act. The opioid crisis is a complex…

Robert E. Latta
Rep. Robert E. LattaR-OH-5 · Jun 12, 2018

Mr. Speaker, I thank the chairman of the committee for all his hard work and for especially shepherding these 57 bills that we got through committee on the opioid crisis that we have in this country.…

Bill Text

3 versions available

Reading Mode
Latest
Referred in SenateIssued June 13, 2018

IIB

115th CONGRESS

2d Session

H. R. 4284

IN THE SENATE OF THE UNITED STATES

June 13, 2018

Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions

AN ACT

To establish a substance use disorder information dashboard within the Department of Health and Human Services, and for other purposes.

1.

Short title

This Act may be cited as the Indexing Narcotics, Fentanyl, and Opioids Act of 2018 or the INFO Act.

2.

Establishment of substance use disorder information dashboard

Title XVII of the Public Health Service Act (42 U.S.C. 300u et seq.) is amended by adding at the end the following new section:

1711.

Establishment of substance use disorder information dashboard

(a)

In general

Not later than 6 months after the date of the enactment of this section, the Secretary of Health and Human Services shall, in consultation with the Director of National Drug Control Policy, establish and periodically update a public information dashboard that—

(1)

coordinates information on programs within the Department of Health and Human Services related to the reduction of opioid abuse and other substance use disorders;

(2)

provides access to publicly available data from other Federal agencies; State, local, and Tribal governments; nonprofit organizations; law enforcement; medical experts; public health educators; and research institutions regarding prevention, treatment, recovery, and other services for opioid use disorder and other substance use disorders;

(3)

provides comparable data on substance use disorder prevention and treatment strategies in different regions and population of the United States;

(4)

provides recommendations for health care providers on alternatives to controlled substances for pain management, including approaches studied by the National Institutes of Health Pain Consortium and the National Center for Complimentary and Integrative Health; and

(5)

provides guidelines and best practices for health care providers regarding treatment of substance use disorders.

(b)

Controlled substance defined

In this section, the term controlled substance has the meaning given that term in section 102 of the Controlled Substances Act (21 U.S.C. 802).

.

3.

Interagency Substance Use Disorder Coordinating Committee

(a)

Establishment

Not later than 3 months after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the Secretary) shall, in consultation with the Director of National Drug Control Policy, establish a committee, to be known as the Interagency Substance Use Disorder Coordinating Committee (in this section referred to as the Committee), to coordinate all efforts within the Department of Health and Human Services concerning substance use disorder.

(b)

Membership

(1)

Federal members

The following individuals shall be the Federal members of the Committee:

(A)

The Secretary, who shall service as the Chair of the Committee.

(B)

The Attorney General of the United States.

(C)

The Secretary of Labor.

(D)

The Secretary of Housing and Urban Development.

(E)

The Secretary of Education.

(F)

The Secretary of Veterans Affairs.

(G)

The Commissioner of Social Security.

(H)

The Assistant Secretary for Mental Health and Substance Use.

(I)

The Director of the Centers for Disease Control and Prevention.

(J)

The Director of the National Institutes of Health and the Directors of such national research institutes of the National Institutes of Health as the Secretary determines appropriate.

(K)

The Administrator of the Centers for Medicare & Medicaid Services.

(L)

The Director of National Drug Control Policy.

(M)

Representatives of other Federal agencies that serve individuals with substance use disorder.

(2)

Non-Federal members

The Committee shall include a minimum of 17 non-Federal members appointed by the Secretary, of which—

(A)

at least two such members shall be an individual who has received treatment for a diagnosis of an opioid use disorder;

(B)

at least two such members shall be an individual who has received treatment for a diagnosis of a substance use disorder other than an opioid use disorder;

(C)

at least two such members shall be a State Alcohol and Substance Abuse Director;

(D)

at least two such members shall be a representative of a leading research, advocacy, or service organization for adults with substance use disorder;

(E)

at least two such members shall—

(i)

be a physician, licensed mental health professional, advance practice registered nurse, or physician assistant; and

(ii)

have experience in treating individuals with opioid use disorder or other substance use disorders;

(F)

at least one such member shall be a substance use disorder treatment professional who is employed with an opioid treatment program;

(G)

at least one such member shall be a substance use disorder treatment professional who has research or clinical experience in working with racial and ethnic minority populations;

(H)

at least one such member shall be a substance use disorder treatment professional who has research or clinical mental health experience in working with medically underserved populations;

(I)

at least one such member shall be a State-certified substance use disorder peer support specialist;

(J)

at least one such member shall be a drug court judge or a judge with experience in adjudicating cases related to substance use disorder;

(K)

at least one such member shall be a law enforcement officer or correctional officer with extensive experience in interacting with adults with a substance use disorder; and

(L)

at least one such member shall be an individual with experience providing services for homeless individuals and working with adults with a substance use disorder.

(c)

Terms

(1)

In general

A member of the Committee appointed under subsection (b)(2) shall be appointed for a term of 3 years and may be reappointed for one or more 3-year terms.

(2)

Vacancies

A vacancy on the Committee shall be filled in the same manner in which the original appointment was made. Any individual appointed to fill a vacancy for an unexpired term shall be appointed for the remainder of such term and may serve after the expiration of such term until a successor has been appointed.

(d)

Meetings

The Committee shall meet not fewer than two times each year.

(e)

Duties

The Committee shall—

(1)

monitor opioid use disorder and other substance use disorder research, services, and support and prevention activities across all relevant Federal agencies, including coordination of Federal activities with respect to opioid use disorder and other substance use disorders;

(2)

identify and provide to the Secretary recommendations for improving Federal grants and programs for the prevention and treatment of, and recovery from, opioid use disorder and other substance use disorders;

(3)

review substance use disorder prevention and treatment strategies in different regions and populations in the United States and evaluate the extent to which Federal substance use disorder prevention and treatment strategies are aligned with State and local substance use disorder prevention and treatment strategies;

(4)

make recommendations to the Secretary regarding any appropriate changes with respect to the activities and strategies described in paragraphs (1) through (3);

(5)

make recommendations to the Secretary regarding public participation in decisions relating to opioid use disorder and other substance use disorders and the process by which public feedback can be better integrated into such decisions; and

(6)

make recommendations to ensure that opioid use disorder and other substance use disorder research, services, and support and prevention activities of the Department of Health and Human Services and other Federal agencies are not unnecessarily duplicative.

(f)

Annual report

(1)

In general

Not later than 1 year after the date of the enactment of this Act, and annually thereafter for the life of the Committee, the Committee shall publish on the public information dashboard established under section 2(a) a report summarizing the activities carried out by the Committee pursuant to subsection (e), including any findings resulting from such activities.

(2)

Recommendation for Committee extension

After the publication of the second report of the Committee under paragraph (1), the Secretary shall submit to Congress a recommendation on whether or not the operations of the Committee should continue after the termination date described in subsection (i).

(g)

Working groups

The Committee may establish working groups for purposes of carrying out the duties described in subsection (e). Any such working group shall be composed of members of the Committee (or the designees of such members) and may hold such meetings as are necessary to enable the working group to carry out the duties delegated to the working group.

(h)

Federal Advisory Committee Act

The Federal Advisory Committee Act (5 U.S.C. App.) shall apply to the Committee only to the extent that the provisions of such Act do not conflict with the requirements of this section.

(i)

Sunset

The Committee shall terminate on the date that is 6 years after the date on which the Committee is established under subsection (a).

Passed the House of Representatives June 12, 2018.

Karen L. Haas,

Clerk.